
    
      This was a randomized, multi-center, open-label, parallel-group, trial of prasterone 200 or
      100 mg/day for 12 months in women with lupus receiving glucocorticoid therapy who had
      completed an earlier 6-month randomized, placebo-controlled study (NCT00053560. Bone Mineral
      Density assessments were performed at baseline and at months 6 and 12.
    
  